A PHASE 2, OPEN-LABEL, PROOF-OF-CONCEPT STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF TAK-411 IN ADULT SUBJECTS WITH CHRONIC INFLAMMATORY
DEMYELINATING POLYRADICULONEUROPATHY (THE CASCA STUDY)
- Registry ID
- TAK-411-2001
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- TAKEDA DEVELOPMENT CENTER AMERICAS INC
- Start date
- 2026-07-09
- Last update
- 2025-03-07
Conditions
- CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)
Related clinical trials
- PHASE 3, RANDOMIZED, DOUBLE-BLINDED, DOUBLE-DUMMY STUDY EVALUATING THE
EFFICACY AND SAFETY OF INTRAVENOUS EMPASIPRUBART VERSUS INTRAVENOUS
IMMUNOGLOBULIN IN ADULTS WITH CHRONIC INFLAMMATORY DEMYELINATING
POLYNEUROPATHY
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY EVALUATING EFFICACY AND SAFETY OF
RILIPRUBART VERSUS INTRAVENOUS IMMUNOGLOBULIN (IVIG) IN PARTICIPANTS WITH CHRONIC
INFLAMMATORY DEMYELINATING POLYNEUROPATHY
- A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY
OF RILIPRUBART IN PARTICIPANTS WITH REFRACTORY CHRONIC INFLAMMATORY DEMYELINATING
POLYNEUROPATHY
- PHASE 2/3, MULTISTAGE, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED PARALLEL GROUP WITHDRAWAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NIPOCALIMAB ADMINISTERED TO ADULTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)
- LONG-TERM TOLERABILITY AND SAFETY OF IMMUNE GLOBULIN INFUSION 10% (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE (HYQVIA/HYQVIA) FOR THE TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)
- PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, MULTICENTER PHASE III STUDY EVALUATING EFFICACY AND SAFETY OF THREE DIFFERENT DOSAGES OF NEWGAM IN PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLY(RADICULO)NEUROPATHY (PROCID TRIAL)
View on source registry